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Biallelic mutations in the gene 
encoding eEF1A2 cause seizures 
and sudden death in F0 mice
Faith C.J. Davies1, Jilly E. Hope1,2, Fiona McLachlan1, Francis Nunez1, Jennifer Doig1, 
Hemant Bengani3, Colin Smith4 & Catherine M. Abbott1,2
De novo heterozygous missense mutations in the gene encoding translation elongation factor eEF1A2 
have recently been found to give rise to neurodevelopmental disorders. Children with mutations in this 
gene have developmental delay, epilepsy, intellectual disability and often autism; the most frequently 
occurring mutation is G70S. It has been known for many years that complete loss of eEF1A2 in mice 
causes motor neuron degeneration and early death; on the other hand heterozygous null mice are 
apparently normal. We have used CRISPR/Cas9 gene editing in the mouse to mutate the gene encoding 
eEF1A2, obtaining a high frequency of biallelic mutations. Whilst many of the resulting founder (F0) 
mice developed motor neuron degeneration, others displayed phenotypes consistent with a severe 
neurodevelopmental disorder, including sudden unexplained deaths and audiogenic seizures. The 
presence of G70S protein was not sufficient to protect mice from neurodegeneration in G70S/− mice, 
showing that the mutant protein is essentially non-functional.
Exome sequencing of parent-child trios has uncovered single gene de novo mutations underlying many previously 
unexplained cases of severe neurodevelopmental disorders. In many cases the genes involved have previously 
been implicated in familial forms of the disorders, but in others, mutations in novel causative genes have been 
uncovered. One such gene is EEF1A2, which encodes translation elongation factor 1A2 or eEF1A2.
Translation elongation is the step in protein synthesis in which aminoacylated tRNAs are delivered to the 
ribosome. This process is facilitated by the elongation factor eEF1A, which delivers the aa-tRNA to the A site of 
the ribosome in a GTP-dependent process. Complete loss of eEF1A leads to the failure of de novo protein syn-
thesis. In vertebrates, there are two independently encoded isoforms of eEF1A, called eEF1A1 and eEF1A21,2. 
Translation elongation factor eEF1A2 is expressed in a very restricted pattern, with expression only being found 
in neurons and muscle (skeletal and cardiac). Other tissues express eEF1A1, which is also present in neurons and 
muscle during development. In mice, eEF1A1 is downregulated after birth until by 21 days, just after weaning, it 
is no longer detectable in muscle, heart and neurons3,4. In adult organisms the two isoforms are mutually exclu-
sively expressed, suggesting functionally equivalent roles in protein synthesis5; this is borne out by the finding that 
either can support translation in in vitro assays6.
A spontaneously occurring deletion of eEF1A2 in mice causes early onset neurodegeneration in mice when 
the mutation is homozygous. This mutation, called wasted (gene symbol wst) results in complete ablation of 
expression of eEF1A2, and homozygous mice die by 28 days at the latest with motor neuron degeneration and 
concomitant muscle wasting. This phenotype is not ameliorated by the forced expression of eEF1A2 in mus-
cle, suggesting that the primary lesion occurs in neurons3,7. Mice that are heterozygous for the wasted deletion 
mutation, on the other hand, not only grow and breed normally, but also show no sign of neurodegeneration or 
impairment of motor function even when aged to 21 months8.
Heterozygous missense mutations in EEF1A2 have now been described in at least 17 individuals9–13. In 
almost all cases these individuals have severe epilepsy, many have autism, and all have developmental delay and 
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intellectual disability. In the most extreme cases the children can be wheelchair bound and unable to make pur-
poseful movements. Thus far 8 distinct amino acid substitutions have been identified. In each case, the mutation 
is seen in the affected child but not in the parents. In such cases, where mutations have arisen de novo and there is 
no inheritance pattern, there is a significant burden of proof that the mutations are actually causative. Clearly, the 
more mutations that are uncovered in a given gene and associated with a specific disorder, the more likely they are 
to be causative. Even so, it is a crucial step towards therapy to determine the mechanism by which the mutations 
cause dysfunction, particularly in the case of heterozygous, dominant mutations.
We carried out experiments to address the effects of disease-causing missense mutations on the function of 
eEF1A2. We used CRISPR/Cas9 genome editing to create mice carrying the G70S mutation, the mutation that 
has been identified in the largest number of patients. Our intention had been to set up a breeding line of mice 
carrying the G70S mutation, but the high frequency of biallelic mutations seen in the gene encoding eEF1A2 
meant that none of the mice carrying the missense mutation survived past 4 weeks. We therefore analysed the 
F0 founder mice; the limitations of this approach, including mosaicism, are addressed further in the discussion.
Many of the mice had biallelic deletions leading to complete loss of function, but even though they had a char-
acteristic wasted neurodegenerative phenotype, we also observed seizures and sudden deaths in these mice. One 
mouse was homozygous for the G70S mutation and was more severely affected than the mice with complete null 
mutations. On the other hand, we show that the presence of eEF1A2 carrying the G70S mutation (in the absence 
of wild-type eEF1A2) is insufficient to prevent neurodegeneration, suggesting that the G70S protein is unable to 
function normally in protein synthesis. These observations, in combination with the lack of seizures seen in het-
erozygous null mice, suggest that there is both a loss of function and dominant negative/gain of function at play 
in the children with missense mutations in eEF1A2.
Results
CRISPR/Cas9 gene editing design. We sought to recreate the mouse equivalent of the clinically important 
G70S mutation in mice. We used CRISPR/Cas9 genome editing; paired gRNAs that target the Eef1a2 gene in the 
region of the mutation, a single stranded oligonucleotide (ssODN) repair template containing the mutation, and 
Cas9 nickase RNA were injected into single cell mouse embryos. The gRNA pair, target region and repair template 
design used are shown in Fig. 1A and B.
The G70S mutation was selected since, at the time, it was the only mutation to have arisen independently three 
times. However, the position of this mutation placed constraints on the design of the ssODN repair template. 
Ideally, the NGG sites targeted by the gRNAs, the so-called “PAM” (protospacer adjacent motif) sites, would 
be mutated to non-NGG sequences in the repair template, preventing subsequent rounds of mutation in the 
Figure 1. CRISPR/Cas9 experimental design and results of genotyping of F0 animals. (A) Diagrammatic 
representation of mouse Eef1a2 gene showing the position of the G70S mutation in exon 3 of Eef1a2.  
(B) Sequence of Eef1a2 in the region targeted in the CRISPR/Cas9 experiment. Underlined sequence indicates 
the ssODN repair template, lower case indicates intron sequence, upper case is coding sequence. Letter in bold 
red indicates the site of the G70S mutation (changed to A in repair template). *Indicates PAM site (protospacer 
adjacent motif), targeted by the gRNA, that was mutated in the template to GTG to prevent further targeting. 
(C) Sequences of alleles recovered in all mice analysed, organised according to the location of the mutation. The 
number on the left corresponds to the mouse code number shown in Supplementary Table 1. Colour coding 
indicates the nature of the mutation.
www.nature.com/scientificreports/
3Scientific RepoRts | 7:46019 | DOI: 10.1038/srep46019
developing mouse embryo that could lead to unwanted deletions. We were able to engineer a change in the site 
targeted by the 3′ gRNA, introducing a silent substitution in order to prevent further mutations after the repair 
template had been incorporated (Fig. 1B). However, the upstream PAM site, targeted by the 5′ gRNA, was too 
close to a splice site to be able to introduce a further mutation without risking unpredicted effects on splicing and 
gene expression. This site was therefore left unmutated in the repair template.
Genotyping shows specific mutations in Eef1a2 in almost all mice. Thirty five mice were born 
after two rounds of injection of the gRNAs, repair template and Cas9n mRNA into fertilised oocytes. DNA was 
purified from ear notches of the mice and the region around the predicted mutation site, spanning both PAM 
sites, was amplified and sequenced. In cases where more than two alleles appeared to be present, or where there 
was any ambiguity in the sequence analysis, the PCR products were cloned and individual clones resequenced. 
Further clarification was obtained where possible by designing allele-specific PCR assays (for example where a 
primer binding site was deleted in one allele, forcing amplification of only the other allele) and sequencing the 
product (Supplementary Figure 1).
Analysis of DNA from the mice showed a variety of different mutations occurring in the region targeted by 
the gRNAs (Fig. 1C, Table 1 and Supplementary Table 1). Only two mice of the 35 born had two wild-type alleles 
(#s 15 and 23). Four mice could confidently be characterised as heterozygous nulls (+ /− ), with wild-type 
sequence on one allele and a deletion close to the PAM site on the other.
A further 23 mice had biallelic mutations in Eef1a2. Of these, 18 had indels on both alleles, presumably as a 
result of the unmutated PAM site being targeted by the Cas9 via non-homologous end joining (NHEJ). One ani-
mal had an allele with a 21 bp in-frame deletion (denoted del/−), but all other alleles were predicted to give rise to 
premature stop codons and nonsense-mediated decay (mice with two such alleles are categorised as −/−). Five 
mice were compound heterozygotes, with a deletion on one allele and clean incorporation of the G70S-causing 
mutation on the other allele (G70S/−). In these cases the G70S mutation had been successfully incorporated by 
homology directed repair (HDR), but NHEJ had resulted in a deletion on the other allele. Only one mouse was 
homozygous for the G70S mutation with no evidence for indels (G70S/G70S). No mice recapitulated the human 
clinically relevant G70S/+ genotype, again presumably due to the high levels of NHEJ resulting from the unmu-
tated PAM site (see below).
The remaining six mice all showed clear evidence of mosaicism. Two could not be genotyped with any accu-
racy as they had complex mutations. In one case, PCR of the region indicated the presence of two mutant alleles, 
with insertions of approximately 50 bp and approximately 250 bp respectively. In the other mouse (#13) amplifica-
tion was unsuccessful from the ear notch DNA but subsequent PCR from brain tissue showed a complex pattern 
of deletions (data not shown). A further four mice were complex mosaics; in two of these there was evidence of 
G70S incorporation on at least one allele but subsequent analysis showed that the missense mutations were in cis 
with deletions and therefore not expressed.
As shown in the summary of genotyping in Fig. 1C, the G70S mutation was incorporated cleanly in seven 
alleles and in cis with indels on a further 9 alleles, showing that HDR had occurred in 18/71 of alleles that could 
be sequenced (allowing for mosaicism). The likely reason for the lack of G70S/+ mice was the high frequency 
of specific deletions in Eef1a2. Most indels found were 1–40 bp deletions located close to the 5′ PAM site on the 
intron/exon boundary (that had not been mutated in the repair template because of the possibility of introducing 
splicing artefacts). Cas9n makes a nick in DNA 3 bp 5′ to the PAM site, and indeed 34 of the alleles sequenced 
contain indels either flanking or within 5 bp of the cut site at the intron-exon boundary. The 3′ PAM site, however, 
was in the coding region, and we had mutated this site in the repair template. In all the alleles sequenced, only two 
contain deletions that cover this 3′ PAM site, and each of those seems likely to have originated at the 5′ site and 
extended to the 3′ PAM (Fig. 1C). These results suggest that it could be important to mutate both PAM sites in 
repair templates in order to minimise subsequent rounds of mutagenesis.
No off-target mutations were detected in any of the mice after amplifying and sequencing DNA around the top 
3 predicted off-target sites for each gRNA (data not shown).
Genome editing of Eef1a2 produced mice with neurodegeneration and susceptibility to seizures. 
All mice were carefully observed from day 14 onwards, weighed regularly, and any abnormal behaviour recorded. 
A summary of the results is shown in Table 1 and in more detail in Supplementary Table 1; all results were 
Genotype* wasted seizure wasted + seizure found dead survived to adulthood other
+ /+ 1 1 (runt)
+ /− 4






Table 1. Summary of outcomes according to genotype. *Determined by genotyping and/or deduced from 
expression analysis. §Survived to 18 days. ¶Survived to 23, 32 and 35 days.
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4Scientific RepoRts | 7:46019 | DOI: 10.1038/srep46019
obtained from analysis of founder (F0) mice as no G70S/+ mice were obtained from which to establish breed-
ing lines. Plots of individual mouse weights and growth curves are shown in Fig. 2. Only the four heterozygous 
null and one wild-type mouse survived. One mouse had no evidence of any mutation in Eef1a2 but was severely 
runted at weaning and had to be culled.
Mice with biallelic deletions (−/−). Six mice with clear-cut biallelic deletions in Eef1a2 had to be euthanised at 
23–25 days as they displayed a phenotype typical of an eEF1A2-null “wasted” mouse. This included weight loss 
after weaning (see Fig. 2), hunched posture, tremors and gait abnormalities (this phenotype is categorised in 
Table 1 as “wasted”).
Eight mice had seizures in response to transient environmental noise. In the first instance, in response to the 
sound of liquid nitrogen being poured in a neighbouring room, six 18 day old mice (including one mosaic) had 
fatal tonic clonic seizures preceded by the wild running typical of an audiogenic seizure. This event occurred 
before any of the typical phenotypic features of a null mouse would have been observed and is categorised in 
Table 1 as “seizure”.
In the second instance, two 23 day old mice, both exhibiting a wasted phenotype (and with clear signs of 
motor neuron degeneration when their spinal cords were examined), had seizures apparently in response to a 
door banging. One died during the seizure; the other recovered but subsequently had to be culled because of the 
wasted phenotype (categorised in Table 1 as “wasted + seizure”).
The remaining four mice with biallelic null mutations died suddenly. The mice appeared healthy and were 
being transferred between animal facilities (which were physically adjoined) but were dead by the time they were 
received less than an hour later. Given the very low threshold of noise required to induce seizures in the other 
mice, it is conceivable that the sudden deaths were also the result of audiogenic seizures. As there were so few 
control mice from this experiment, and the noises were incidental, we can not evaluate the incidence of audio-
genic seizures statistically, but no other mice in the facility have ever been observed to have seizures in response 
to similar environmental sounds.
Those − /− mice from which spinal cords were able to be obtained showed variable but clear-cut evidence of 
motor neuron degeneration (Fig. 3). The sections showed a range of degenerative pathology ranging from essen-
tially normal through to striking neuronal nuclear enlargement and cytoplasmic degeneration. An intermediate 
stage was also seen, with significant cytoplasmic vacuolation but no obvious nuclear changes.
Figure 2. Body weights of F0 mice from weaning. Mouse weights between postnatal day 17 and 30. Upper 
panel shows data expressed as one dot per mouse per measurement; mouse genotype is indicated by colour 
of dot. The lower panel shows mean (dot) and standard error at different timepoints for each genotype. Since 
there was only one WT mouse in the F0 litters, additional body weights for genetically matched control mice 
were included. Note that the only G70S/G70S mouse is not included in this analysis as it had been culled before 
weighing began. One-way ANOVA performed on body weights from P23 and, separately, P25, showed that the 
body weights of mice with biallelic mutations were significantly different from those of + /− and wildtype mice 
(P < 0.0001 for both P23 and P25). Tukey’s multiple comparison test subsequently showed that the G70S/− 
and − /− weights were significantly different from wildtype and + /− , on both P23 and P25. Body weights for 
G70S/− and − /− , and for + /− and + /+ were not significantly different.
www.nature.com/scientificreports/
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Compound heterozygous mice (G70S/−). Five mice were found to have incorporated the G70S missense muta-
tion cleanly on one allele and to have a deletion on the other allele, with no sign of mosaicism. These mice all 
appeared to have a phenotype typical of mice that express no eEF1A2. They were indistingishable from their 
homozygous null littermates and had to be culled at 23–25 days (see Fig. 2).
We were able to analyse spinal cord sections from three of the G70S/− compound heterozygous mice (#1, 10 
and 17). All showed clear signs of neurodegeneration (Fig. 3) and the degree of weight loss and overall observable 
condition were indistinguishable from those of the null mice (Fig. 2).
Homozygous G70S/G70S mouse. One mouse exhibited what appeared to be a more severe than usual wasted 
phenotype. Although mice which are null for eEF1A2 do not show any outward signs of the wasted phenotype 
until at least 21 days, and normally survive until at least 23–28 days, this mouse had to be euthanised at 18 days. 
It was smaller than its littermates (most of which were later shown to be complete nulls), and displayed tremors 
and shakiness. This was the only mouse which was subsequently found to be homozygous for the G70S mutation. 
This suggests that homozygosity for the missense mutation might result in a more severe effect than that seen in 
homozygous null animals, but as only one mouse had this genotype this result has to be interpreted with extreme 
caution.
Mosaic mice. Of the remaining mice, five were clear mosaics. The mosaicism is presumed to result from 
Cas9-induced mutagenesis continuing after the first cell division in the embryo.
One of the mosaic mice died of what appeared to be an audiogenic seizure at 18 days (as described above) and 
another was found dead at 23 days. The other three mosaic mice also displayed characteristic wasted features of 
tremor, weight loss and unsteady gait, but two of these survived longer than any typical wasted mouse, until 32 
and 35 days respectively (Table 1). A further mouse, #13, which had a complex pattern of deletions on sequencing, 
survived to 29 days. One of the mosaic mice that had to be euthanised at 23 days had previously had a seizure 
lasting about two minutes, with repeated rearing and shaking.
Expression analysis of eEF1A2 in mutant mice shows the G70S mutant protein is unable to compensate for the loss of 
wild-type eEF1A2. Tissue samples were collected from all mice with bilallelic or mosaic mutations, and muscle 
and brain protein extracts analysed by Western blotting with anti-eEF1A antibodies.
Initially, we used an antibody that was raised against full length eEF1A protein. This antibody does not distin-
guish between eEF1A1 and eEF1A2, but was used to establish whether any smaller bands were detectable in any 
samples, that would represent truncated products that could be missed by the isoform-specific anti-peptide anti-
bodies. In fact, no bands were seen in any sample other than the expected band at ~50 kDa (data not shown). An 
antibody that is specific to the eEF1A2 isoform was then used to examine expression in the same brain extracts 
from all animals with mutations. Brain samples from all mice carrying a G70S mutation were then run in tripli-
cate together with additional control samples for quantification. Representative blots and a summary of the results 
are shown in Fig. 4.
Expression of eEF1A2 in brain of mice identified as having biallelic deletion mutations was at background 
level in all cases, comparable to that seen in tissue extracts from wasted mice (representing complete nulls). Only 
Figure 3. Neurodegeneration in the spinal cords of mice with mutations in eEF1A2. H&E stained sections 
of of spinal cord taken from G70S/− (left) and null (right) mutant mice, with age matched control section on far 
right. Normal neurons are indicated by arrows with dotted lines. Dashed line arrows indicate neurons showing 
nuclear vacuolation and solid arrows indicate degenerating neurons with marked cytoplasmic vacuolation.
www.nature.com/scientificreports/
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a trace of expression was seen in brain from mouse #14, that had an in-frame deletion. All mosaic mice apart from 
#31 (that had to be euthanised at 23 days along with the null mice) had detectable expression of eEF1A2 (Fig. 4A).
Strikingly, mice with the G70S mutation on at least one allele showed levels of expression of eEF1A2 in brain 
comparable to that seen in wild-type mice (Fig. 4B). Additional analysis was carried out in order to quantify 
expression in the mutant mice relative to the mean value from three wild-type control samples. All samples were 
analysed in triplicate. As shown in Fig. 4C brain from G70S/− mice expresses eEF1A2 at levels comparable to 
those seen in samples from age-matched WT mice. Since the G70S/− mice analysed (#1, 10 and 20) all had clean 
incorporation of the G70S mutation on one allele and a deletion on the other the protein that was being expressed 
was predicted to have originated from the G70S mutant allele. Further, mouse #4, a G70S/G70S homozygote also 
expressed eEF1A2 brain at levels equivalent to wild-type controls.
In order to determine whether the protein being produced in the apparently G70S/− mice did indeed derive 
from the allele bearing the G70S missense mutation, we carried out RT-PCR on brain samples from all mutant 
mice carrying a G70S mutation on at least one allele (Fig. 4C). The repair template had been designed such that 
incorporation would result in the loss of an MnlI site if the G70S mutation was created, allowing us to determine 
whether any detectable transcript was derived from the mutant allele. The MnlI digest of brain RT-PCR products 
showed that in each of the mice thought to be compound G70S/− heterozygotes (#1, 10, 17, 20 and 33) and the 
G70S homozygote (#4) the only allele detectable at the RNA level contained the G70S mutation (Fig. 4C). In the 
case of G70S/− mouse #20 (not shown), the downstream MnlI site had been lost due to a silent mutation, but the 
pattern confirmed the presence of the G70S site). This demonstrates that the protein detected by Western blotting is 
actually the G70S containing mutant eEF1A2, and that even high levels of expression of the mutant protein in brain 
are insufficient to protect mice from developing a phenotype consistent with that seen in homozygous null mice.
Discussion
We used CRISPR/Cas9 genome editing to create mice with mutations specifically in the gene encoding eEF1A2, 
with a high level of efficiency. Whilst a quarter of all alleles recovered contained the desired point mutation 
encoding the G70S missense mutation, a large number of mice also had deletions. Twenty eight of the 35 mice 
born after two rounds of injections had mutations on both alleles of Eef1a2, and 94% had at least one specific 
mutation in Eef1a2.
Although no mice were obtained that recapitulate the clinically important, neurodevelopmental 
disorder-causing genotype seen in humans, G70S/+ , we did recover a range of mice with phenotypes relating 
to epilepsy and neurodegeneration. Firstly, fourteen mice displayed weight loss, hunching, tremors and gait 
Figure 4. Expression analysis of mice with mutations in eEF1A2. (A) Representative western blot showing 
eEF1A2 expression in protein extracts from brains of mutant founder mice from the CRISPR gene targeting 
experiment. The negative control was a brain extract from a wasted mouse (denoted − /− ) and the loading 
control was GAPDH. The blot images are cropped for clarity and a larger area is shown in the Supplementary 
Data File. (B) Quantification of eEF1A2 expression in brain samples from mice with key genotypes. Controls 
were aged matched wild-type mice that were offspring of the F0+ /− heterozygous mice. Expression levels are 
derived from three repeats of the Western analysis, normalised to GAPDH and expressed relative to the average 
obtained from three independent wild-type controls. **Indicates p < 0.01, n.s means not significant. (C) MnlI 
digests of RT-PCR products from brain RNA of mice of different genotypes. Predicted band sizes are shown to 
the right of the gel. The absence of bands at 73 bp and 39 bp in the G70S/− and G70S/G70S mice suggests that 
no wild-type allele is being expressed.
www.nature.com/scientificreports/
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disturbances typical of wasted (eEF1A2 null) mice. These mice were typically euthanised at 23 days. A further 
four mice were mosaics and developed a similar phenotype but survived until up to 35 days.
Of the mice that appeared to have a typical eEF1A2-null phenotype, four were in fact G70S/− compound 
heterozygotes that were actually expressing the mutant protein in brain at levels comparable to that seen in 
wild-type mice. We know from earlier work that the eEF1A2-null phenotype is not ameliorated by expression of 
eEF1A2 in muscle, so lack of expression in brain and spinal cord is responsible for the phenotypic abnormalities7. 
Heterozygous null mice have no apparent motor defects and live a normal lifespan, in contrast to the G70S/− 
mice that had to be culled by 23 days at the latest. The failure of the G70S mutant protein, even at high levels, to 
protect mice from developing a phenotype typical of eEF1A2-null animals suggests strongly that the missense 
mutation renders the protein essentially non-functional, at least in terms of whole animal physiology. Further 
work is needed to examine function at a biochemical level, but since heterozygous null animals are essentially 
normal and have never been observed to have seizures, we can be confident that the G70S mutant protein is 
severely compromised.
There is also a suggestion that the mutant protein could have acquired a level of toxicity reflecting a domi-
nant negative or gain of function mechanism. The phenotype of the only G70S/G70S homozygous animal was 
more severe than in its nine null littermates, and this animal was euthanised at 18 days (by investigators blind to 
genotype). However, any result based on a single animal must be regarded as extremely preliminary, and further 
lines of mice will clearly need to be made in order to establish whether this is a consistent finding, suggestive of a 
dominant negative or gain of function mechanism.
The second phenotype in the mice relating to the human condition was seen in 8 mice, all with biallelic 
mutations (one mouse, #8, showed the presence of a wild-type allele on ear clip DNA analysis but must never-
theless have been a mosaic, as it did not express eEF1A2 in either brain or muscle). These eight mice suffered 
what appeared to be audiogenic seizures that were fatal in all but one case. Two of the 8 animals also exhibited a 
typical wasted phenotype but the remaining 6 died of their seizures at 18 days, having shown no sign of weight 
loss, tremors or ataxia. This lack of a neurodegenerative phenotype was not unexpected as wasted mice do not 
show any of these phenotypic features until at least 21 days14. It can be assumed, since none of the mice in this 
group were expressing eEF1A2, that they would have gone on to develop a neurodegenerative phenotype had 
they recovered from their seizures. The original line of wasted mice has not been reported to show susceptibility 
to audiogenic seizures, so it is possible that our F0 null mice were more susceptible due to genetic background 
differences. Alternatively the random nature of the environmental triggers, coupled with the close observation of 
the CRISPR-generated mice, could have led to an ascertainment bias.
Four mice died suddenly, three of them within an hour of having been seen, apparently healthy. The cause of 
death in these cases could not be established. It is possible that the deaths represented sudden death in epilepsy 
(SUDEP). SUDEP is a known, extreme, consequence of epilepsy responsible for a significant proportion of deaths 
in individuals with childhood-onset epilepsy. SUDEP has also been seen in a number of mouse models of epi-
lepsy, for example mice with a knock-in of the Q390X mutation in the Gabrg2 gene, which can suffer SUDEP at 
any stage15 and those with a heterozygous knock-in of N1768D in the Scn8a gene; these mice also exhibit seizures 
and SUDEP16. An alternative explanation for the sudden deaths in the eEF1A2-null mice is neurodegeneration of 
brainstem nuclei leading to respiratory arrest. Again, further lines will be need to be generated, as analysis of F0 
mice does not allow for the level of experimental planning required to resolve such issues.
These results represent a potential new example of the emerging links between neurodegeneration and epi-
lepsy. Both SUDEP and audiogenic seizures have been linked to neurodegeneration of the brainstem, and it is well 
established that uncontrolled seizures and status epilepticus can lead to neuronal death. However, the linking of 
pathways that can lead to both neurodegeneration and epilepsy has only recently been recognised. It is difficult to 
establish the effects of loss of eEF1A2 on the brain as mutant animals die as a result of severe neurodegeneration 
in the spinal cord, but since motor neurons lacking eEF1A2 degenerate and die (presumably due to a failure to 
carry out de novo protein synthesis) it is reasonable to assume that neurodegeneration would also occur in the 
brain if the mice survived longer. Similarly, the strain of Gabrg2 mutant mice described above show widespread 
neurodegeneration in addition to their epilepsy and SUDEP phenotype, in this case caused by accumulation and 
intracellular aggregation of mutant GABAA receptor subunits15. Whilst there is no evidence that intracellular 
aggregates are forming in the eEF1A2-mutant mice, one of the disease causing mutations in humans, E122K, has 
been shown to be associated with translational infidelity in yeast17, a process that would be predicted to lead to 
accumulation of misfolded proteins. However, without additional lines it remains possible that there is no func-
tional connection between the seizures and neurodegeneration in our F0 mice.
Both translation elongation factors eEF1A1 and eEF1A2 have been identified at the synapse in transcriptomic 
and proteomic experiments18,19. It seems highly probable that de novo protein synthesis at the synapse, necessary 
for synaptic plasticity and memory consolidation, is perturbed in humans with missense mutations in eEF1A2. 
The most common cause of inherited intellectual disability and autism, Fragile X syndrome, also shows disrup-
tion of protein synthesis at the synapse. Whilst in the case of Fragile X syndrome protein synthesis is upregulated, 
it has been suggested that small changes in synaptic protein synthesis, either up or down, can result in neurode-
velopmental disorders20. Interestingly, one of the key phenotypic features seen in mouse models of Fragile X 
syndrome is an increased susceptibility to audiogenic seizures21, suggesting the possibility of mechanistic links 
between disorders caused by mutations in eEF1A2 and FMRP, via a convergence on synaptic protein synthesis. 
There is no evidence that translation elongation factors have any specificity in terms of mRNAs that are being 
translated, so any mutational effect would likely be at the level of global protein synthesis.
The G70S mutation is at a highly conserved amino acid adjacent to the eEF1B binding site, so is predicted to 
show reduced binding to the eEF1B GTP exchange factor. It is also predicted to affect protein stability, but in fact 
our results suggest that the protein is expressed at levels indistinguishable from that of the equivalent unmutated 
protein. It is hard to predict with any confidence whether G70S would result in gain or loss of function, but the 
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mutational spectrum of EEF1A2 suggests that heterozygous loss of function mutations would be either tolerated 
or lethal, as all clinical mutations identified so far have been missense. In fact no loss of function mutations in 
EEF1A2 are seen in the 60 K genomes in ExAC22, and EEF1A2 is one of a few thousand genes judged to be subject 
to excessive constraint23.
Some useful parallels can be drawn between the effects of mutations in eEF1A2 and disorders associated 
with mutations in tRNA synthetases (since the primary role of eEF1A2 is downstream, to bring aminoacylated 
tRNAs to the ribosome). Homozygous loss of function mutations in humans in QARS (encoding glutaminyl 
tRNA synthetase) result in severe epilepsy associated with developmental defects in the brain24 and similar muta-
tions in AARS (encoding alanyl tRNA synthetase) result in myelination defects25. On the other hand, mice that 
are homozygous for an editing-defective mutation in Aars exhibit ataxia and Purkinje cell loss accompanied by 
a build-up of misfolded proteins26. One of the epilepsy-causing mutations in EEF1A2 in humans, E122K, has 
been shown to be associated with translational infidelity in yeast17 and also results in ataxia in patients11. Neurons 
could be particularly vulnerable to the effects of misfolded proteins resulting from failures of proofreading during 
protein synthesis.
This study is one of relatively few to examine mutant phenotypes in the F0 generation resulting from CRISPR/
Cas9 genome editing. In our case we had no choice but to analyse founder mice as the phenotype was fatal in all 
the animals carrying the desired mutation, and no G70S/+ animals were recovered. Although analysis of F0 mice 
was not our intended experimental design, such a strategy has actually been proposed on the basis that CRISPR 
is so efficient that the breeding of animals could be avoided27. This methodology is reliant on the absence of con-
sistent off-target effects, low levels of mosaicism, and the availability of sufficient numbers of mice to be able to 
avoid the confounding effects of rare off-target mutations. Large numbers of mice are also needed where different 
animals have different indels, as even subtly different deletions can have distinct effects on gene expression and 
splicing.
A number of recent studies have demonstrated the need for caution in interpreting results based on analysis 
of F0 animals only. Yasue et al used wild type Cas9 and a single gRNA in mice to target Fgf10, loss of function of 
which is known to confer an abnormal limb phenotype. They collected 25 F0 embryos and showed that although 
96% had evidence of NHEJ repair, only 56% had limb defects. Four embryos had up to 4 distinct alleles. Thus 
although mutagenic efficiency was high, analysis was complicated by the presence of both mosaicism and reduced 
penetrance. Further experiments yielded some embryos with in-frame deletions, another potential complica-
tion for interpretation of results28. Fujii et al, on the other hand, targeted three independent genes in a single 
experiment, obtaining 9 F0 pups with mutations at all three loci. These pups displayed knockout phenotypes and 
transmitted mutations to the next generation, arguing against the presence of significant mosaicism29. However, 
small numbers of animals were studied, and it is possible that the risk of off-target mutations would increase with 
the number of genes being targeted.
One of the few studies to look for off-target mutations at sites not predicted by online CRISPR design tools 
used exome sequencing of F1 knock-in mice generated using homology directed repair30. This study was small, 
examining DNA from only 4 mice, but one insertion and one deletion was found in one of the mice, and an inser-
tion in a further mouse; two of these mutations would be predicted to be deleterious. By breeding on from these 
lines, the off-target mutations would in most cases segregate away from the desired mutation so that confounding 
effects on the phenotype could be identified. Clearly, though, if only F0 animals are being studied and off-target 
mutations are non-random, phenotypic analysis could be misleading.
One study, on the other hand, made positive use of the mosaicism seen in F0 animals. Zhong et al targeted 
Kcnj3 (mutations in which cause blindness) using wild-type Cas9 and a single gRNA to generate mutations by 
NHEJ. Null mutations in Kcnj3 are lethal postnatally, so that a conditional strategy would normally have to be 
employed. In the Zhong study, 8 surviving F0 mice showed mosaicism in the retinal pigmented epithelium, ena-
bling the authors directly to compare patches of mutant and WT cells in the eye31.
In our experiment, one of very few to examine F0 offspring from an experiment designed to use HDR via a 
repair template, a number of mice were clearly identified as mosaic because of the presence of more than two 
distinct alleles in ear-notch DNA. However, it remains possible that in other cases there were lower levels of 
mosaicism, for example in specific areas of the brain, that could further confound the interpretation of our results. 
Indeed, one animal showed evidence of low level mosaicism when expression was examined by RT-PCR even 
though there had been no indication of this when the DNA was analysed. Clearly this level of complication 
requires large numbers of F0 mice to be generated in order to obtain meaningful results. We saw no mutations at 
predicted off-target sites; we can not rule out the possibility of apparently random off-target events, but our use 
of paired gRNAs and the nickase form of Cas9 should have minimised this possibility. Fortunately we were able 
to retrieve a number of mice with identical mutations where HDR had been successful, allowing us to analyse the 
effects of the missense mutation on a null background. Our prior knowledge of the homozygous null phenotype 
was extremely useful in interpreting our results; we saw no real heterogeneity of expression levels in the mice 
with homozygous deletions other than those explained by mosaicism. It is worth noting, though, that we saw 
cases where the missense mutation had been introduced by HDR but where there was a deletion on the same 
allele, presumably due to a subsequent NHEJ effect. This illustrates the need for careful genotyping for correct 
interpretation of results.
With the caveats described above, our results suggest that the G70 missense mutation in eEF1A2 severely 
compromises protein function and may even be toxic to the cell. We also show that the presence of biallelic muta-
tions in eEF1A2 in mice can result in seizures and sudden death, providing the first evidence of a link between 
eEF1A2 and epilepsy in a model organism. There remains, though, an urgent need for animal models that faith-
fully recapitulate the human heterozygous condition. Without such models it is not possible to be certain whether 
any therapeutic strategy should be aimed at boosting expression of the mutant form of eEF1A2, or at restoring 
www.nature.com/scientificreports/
9Scientific RepoRts | 7:46019 | DOI: 10.1038/srep46019
expression of eEF1A2 to wild-type levels whilst preventing expression of the mutant protein. The efficiency of 
CRISPR/Cas9 gene editing has put the generation of these animal models within reach.
Materials and Methods
CRISPR/Cas9n gene editing. Guide RNA pairs were designed from target sequence of mouse Eef1a2 
around exon 3 using online tools at DNA 2.0 and at http://crispr.mit.edu/. They were synthesised, annealed and 
cloned into vector px458 from which they were in vitro transcribed before microinjection. The sequences were 
amplified using universal reverse primer and T7 tagged forward primers. The guide RNA PCR template was used 
for in vitro RNA synthesis using T7 RNA polymerase, and the RNA template was subsequently purified using 
RNeasy mini kit (Qiagen) purification columns. Cas9 (nickase) mRNA was procured from Tebu Bioscience. The 
repair template was designed and ordered as an ssODN Ultramer from IDT.
Microinjection: samples were prepared and injected into C57BL/6 single cell embryos at the following con-
centrations: gRNAs 25 ng/ul each, Cas9n mRNA at 50 ng/ul and Ultramer ssODN repair template 150 ng/ul. Prior 
to the experiment described here, a different gRNA pair was tested and the resulting embryos collected; as only 
three embryos out of 71 had incorporated the G70S mutation (data not shown) the design was modified in order 
to achieve higher rates of targeted mutagenesis (Fig. 1).
Transgenic mouse generation. Mice were housed in the Biomedical Research Facility (BRF) at the 
University of Edinburgh. All mice were maintained in accordance with Home Office regulations and all protocols 
had been approved by the local ethics committee of the University of Edinburgh. All methods were performed 
in accordance with the relevant guidelines and regulations. Embryo transfer was carried out with short term 
recovery anaesthesia, and analgesia where needed post-operatively. Mutant mice were closely observed for overall 
clinical condition and were euthanized where necessary to avoid suffering.
Transgenic mice were made using standard pronuclear injection methods of CRISPR reagents into oocytes 
derived from C57BL/6J mice. There were 35 live born mice as a result of this procedure; those that survived 
weaning were housed in small single sex groups. Both male and female mice were characterised; both males and 
females were seen in all groupings according to phenotype/outcome. All phenotyping was carried out blind to 
genotype.
Genotyping. Ear notches were taken at weaning, DNA extracted and used for PCR genotyping, initially by 
restriction digests to detect the presence/absence of the MnlI site destroyed if the G70S mutation had been intro-
duced, and then by direct sequencing. This sequence information was used to design further allele specific PCR/
sequencing assays for the 14 mice that had identifiable small deletions that could be used for primer design to 
selectively amplify the other allele(s). This product could then be sequenced, providing a straightforward method 
to sequence a single allele without the need to subclone PCR products.
PCR products from eight mice were TOPO cloned either because they hadn’t been suitable for allele-specific 
sequencing, or because the allele-specific sequencing results indicated probable mosaicism. DNA from G70S 
mouse #4 was also TOPO cloned for confirmation of genotype, as this was the only likely homozygous knock-in 
of the cohort.
Off-target analysis. Genomic DNA around the top off-target sites predicted by the DNA2.0 tools were 
amplified by PCR and the products sequenced.
RNA analysis. RNA from brain was extracted using the QIAGEN RNeasy mini kit and DNase digested using 
the QIAGEN RNase-Free DNase Set. cDNA was then synthesized using the Agilent Technologies AffinityScript 
Multi Temperature cDNA Synthesis Kit. RT-PCR was performed on the cDNA using primers for eEF1A2 
(5′ GCCACGATCAGCACTGCG and 5′ CAAGCGGACCATCGAGAAGT; Sigma). 1 μ l of each cDNA sample 
was added to 24 μ l of PCR reaction mix and run on a touchdown PCR program for 24 cycles for eEF1A2 and 30 
cycles for actin. Products were checked on a 2% agarose gel. Products were then digested with MnlI or AciI (NEB) 
and 15 μ l each sample run on 2 or 2.5% agarose gels.
Protein analysis. Protein extracts were made from muscle (hind limb) and brain from each analysable 
mouse. Tissues were homogenised in 0.32 M sucrose using a bead homogeniser and centrifuged at 10,000 g at 4 °C 
for 10 minutes. The supernatant was removed and mixed 1:1 with Laemmli buffer. Samples were boiled at 95 °C 
for 10 minutes, 10% (v/v) DTT added then loaded onto a 10% polyacrylamide gel and run at 120 V for 1.5 hours. 
The gel was then transferred at 100 V for 1 hour onto a PDVF membrane. Membranes were incubated in 7% acetic 
acid and 10% methanol for 15 minutes, washed 4 times for 5 minutes in dH2O and incubated in SYPRO Ruby 
stain for 15 minutes. Total protein was then imaged on the Odyssey Fc Imaging System (LI-COR) and membranes 
were blocked for 1 hour in Odyssey blocking buffer (LI-COR). Blots were incubated with primary antibodies for 
eEF1A2 (Rabbit; Proteintech; 1:500) and GAPDH (Mouse, Millipore, 1:1000) in Odyssey blocking buffer at 4 °C 
overnight then washed in PBST 3 × 5 minutes and incubated in IRdye 800CW anti-mouse (LI-COR) or IRdye 
680RD anti-rabbit (LI-COR) secondary antibodies at 1:5000 for 1 hour at RT. Images were analysed using ImageJ 
software to assess band intensity and values expressed relative to the loading control. Differences in expression 
between mice with the G70S/− , − / − and + /+ genotypes were assessed by one way ANOVA with tukey post-hoc 
testing.
Pathology. Spinal cords were collected and fixed from just under half the mice with biallelic mutations 
together with aged matched C57BL/6 controls. The fixed spines were delcalcified and sectioned. H&E stained 
sections were examined by an experienced neuropathologist.
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